Tzield Injection
NDC 73650-316
Product Information
Tzield (teplizumab-mzwv) is a BLA-approved product labeled by Provention Bio, Inc.. This medication is typically used as a cd3-directed antibody interactions [moa]. It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 73650-316 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 73650-316?
What are the uses of this product?
What are Active Ingredients of this product?
- TEPLIZUMAB 1 mg/mL - a humanized anti-CD3 monoclonal antibody that has been mutated to reduce Fc receptor and complement binding, used in treatment of type I diabetes
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TEPLIZUMAB (UNII: S4M959U2IJ)
- TEPLIZUMAB (UNII: S4M959U2IJ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE (UNII: E1W4N241FO)
- SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2621885 - teplizumab-mzwv 2 MG in 2 ML Injection
- RxCUI: 2621885 - 2 ML teplizumab-mzwv 1 MG/ML Injection
- RxCUI: 2621885 - teplizumab-mzwv 2 MG per 2 ML Injection
- RxCUI: 2621891 - Tzield 2 MG in 2 ML Injection
- RxCUI: 2621891 - 2 ML teplizumab-mzwv 1 MG/ML Injection [Tzield]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.